Resilience is the human capacity to respond positively to adverse situations, enabling individuals to achieve, maintain, or recover physical or emotional health after devastating illness, losses, or other stressful situations. Resilience may be an important factor in health promotion. Objectives: The aim of this study was to evaluate resilience and possible associated factors in patients with systemic lupus erythematosus (SLE). Methods: In a cross-sectional study, 123 SLE women and 133 age-matched controls were evaluated using the Spanish version of Wagnild and Young's Resilience Scale (WYRS, 1993). SLE patients underwent a structured interview to collect sociodemographic data, including socioeconomic status measured by the Graffar method. The Center for Epidemiologic Studies Depression Scale (CES-D) was used to measure depressive symptoms. 
and ≥1 visit during the last year of our database were included. Those with menopause were excluded. We analyzed demographic data; disease duration; antiphospholipid antibodies (aPL) and antiphospholipid syndrome (APS) (Sapporo 2006); socioeconomic status (Graffar scale); disease activity (SELENA-SLEDAI) and accrual damage (SLICC); use of teratogens: Methotrexate (MTX), Mycophenolate (MYC), Cyclophosphamide (CYC), biologic drugs (BD), self-reported sexual status (active/non active) and CM: intrauterine device (IUD), condom (Cdm) and hormonal contraceptive pill (CP). Results: 132/219 were included. Female 91.6%, age: 30.1 (16-49) years, disease duration: 38.5 (1-324) months, SELENA-SLEDAI: 3.5 (0-29), SLICC: 0.5 (0-5). Sexual status and use of CM: were available for 120 patients. Sexually active (SA) 73%, female 77%. CM in SA patients: 74%: 5% CP, 77% Cdm and 18% IUD. CM in female patients stratified by Graffar (GF): GF I (n=1): none SA; GF II: (n=19): 84% SA, 75% of them used CM (75% Cdm, 25% IUD); GF III (n=33): 82% sexually active, 81% used CM (86% Cdm, 14% IUD), GF IV (n=41) 75% SA, 68% used CM (9% CP, 71% Cdm, 19% IUD), GF V (n=4) 100% SA, 50% used CM (50% CP, 50% Cdm); GF NA (n=11) 55% SA, 83% used CM (80% Cdm, 20% IUD). CM in female patients stratified by SLE activity: SLEDAI <3 (n=62): 76% SA, 77% of them used CM (3% CP, 83% Cdm, 14% IUD); SLEDAI 3-12 (n=42): 81% SA, 76% used CM (8% CP, 69% Cdm, 23% IUD); SLEDAI >12 (n=60): 60% SA, 67% used CM (100% Cdm). CM in female patients using teratogenic drugs: MTX (n=8): 100% SA, 75% of them used CM (17% CP, 66% Cdm, 17% IUD); MYC (n=20): 80% SA, 88% used CM (71% Cdm, 29% IUD); CYC (n=3): 33% SA, 100% used CM (100% Cdm); Belimumab (n=1): 100% SA, 100% surgical CM (tubectomy). aPL was evaluated in 96/132 patients. 17/96 had positive aPL and 5/17 fulfilled APS criteria. 2/17 patients had no CM data available, none with APS. 9/17 patients with aPL were female, 55% SA and all of them used Cdm. 3/5 patients with APS were female, all SA, 66% used Cdm. Conclusions: Condom was the most reported CM. Use of CM was more frequent in the upper social stratus (GF I-III) respect to the lower (GF IV-V). The proportion of sexually active female patients was similar in those using teratogenic drugs compared with who had not used them. The self-reported sexual status was similar despite of SLEDAI stratification, being similar in patients with low or high disease activity. We deem necessary education, counseling and evaluation of use of the CM in every visit of patients with SLE. 
